| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Novavax Inc (NVAX) has 8 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. NVAX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 264.1K | $2.38M | - | |
| CFO | 145.1K | $1.31M | - | |
| VP | 112.7K | $1.01M | - | |
| VP | 34.9K | $313.9K | - | |
| Dir | 28.5K | $256.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2017 | Trizzino John86 | SVP, Commercial Operations | Buy | 3,401 | $1.12 | $3,809.12 | +4.0% | |
| Jan 31, 2017 | Herrmann John A III91 | SVP, General Counsel | Buy | 4,960 | $1.12 | $5,555.20 | +234.8% | |
| Jan 31, 2017 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 1,633 | $1.12 | $1,828.96 | +16.4% | |
| Dec 7, 2016 | Glenn Gregory M88 | President, R&D | Buy | 1,000 | $1.45 | $1,446.00 | +29.2% | |
| Sep 22, 2016 | Trizzino John86 | SVP, Commercial Operations | Buy | 46,000 | $2.17 | $99,820.00 | +116.3% | |
| Sep 21, 2016 | McManus Michael A Jr81 | Director | Buy | 30,000 | $1.61 | $48,297.00 | +13.8% | |
| Sep 21, 2016 | Douglas Richard | Director | Buy | 100,000 | $1.72 | $172,010.00 | +40.0% | |
| Sep 21, 2016 | Glenn Gregory M88 | President, R&D | Buy | 1,000 | $1.65 | $1,649.00 | +41.2% | |
| Sep 20, 2016 | Boudreaux Gail | Director | Buy | 100,000 | $1.45 | $144,850.00 | +100.0% | |
| Jul 31, 2016 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 422 | $4.29 | $1,810.38 | +4.4% |